What is a safe discontinuation plan for a patient taking Xanax (alprazolam) 0.25 mg twice daily (BID)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 4, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Safe Discontinuation of Xanax 0.25 mg BID

For a patient on alprazolam 0.25 mg twice daily (total 0.5 mg/day), reduce the dose by 10-25% of the current dose every 1-2 weeks, which translates to decreasing by 0.125 mg (one-quarter tablet) every 1-2 weeks until complete discontinuation is achieved over approximately 6-8 weeks. 1

Critical Safety Framework

Abrupt discontinuation of alprazolam is never appropriate and can cause seizures and death—this risk exists even at low doses like 0.5 mg/day. 1, 2 The FDA explicitly warns that withdrawal symptoms, including seizures, have been reported after only brief therapy with alprazolam at doses within the recommended range (0.75 to 4 mg/day), and signs and symptoms of withdrawal are more prominent after rapid decrease or abrupt discontinuance. 2

Recommended Tapering Protocol

Week-by-Week Schedule

Always reduce by a percentage of the current dose, not the original dose, to prevent disproportionately large final reductions. 1

  • Weeks 1-2: Reduce from 0.5 mg/day to 0.375 mg/day (25% reduction)

    • Take 0.25 mg in morning, 0.125 mg in evening 1
  • Weeks 3-4: Reduce to 0.25 mg/day (approximately 33% of current dose)

    • Take 0.125 mg twice daily, or 0.25 mg once daily 1
  • Weeks 5-6: Reduce to 0.125 mg/day (50% of current dose)

    • Take 0.125 mg once daily 1
  • Weeks 7-8: Extend dosing interval before complete discontinuation

    • Take 0.125 mg every other day for 1-2 weeks, then discontinue 1

The taper rate must be determined by the patient's tolerance, not a rigid schedule, and pauses are acceptable and often necessary when withdrawal symptoms emerge. 1

Monitoring Requirements

Follow up at least monthly during the taper, with more frequent contact (weekly or biweekly) during difficult phases. 1 At each visit, assess for:

  • Withdrawal symptoms: anxiety, tremor, insomnia, sweating, tachycardia, headache, weakness, muscle aches, nausea, confusion 1, 2
  • Severe symptoms requiring immediate attention: seizures, altered mental status, severe psychological distress, panic attacks, suicidal ideation 1
  • Functional status: ability to maintain daily activities 1

Adjunctive Strategies to Improve Success

Non-Pharmacological Support (Highest Priority)

Integrate cognitive-behavioral therapy (CBT) during the taper, as this significantly increases success rates. 1 Additional supportive measures include:

  • Mindfulness and relaxation techniques 1
  • Sleep hygiene education 1
  • Exercise and fitness training 1
  • Patient education about benzodiazepine risks and benefits of tapering 1, 3

Pharmacological Adjuncts (If Needed)

Gabapentin can help mitigate withdrawal symptoms: Start with 100-300 mg at bedtime or three times daily, increasing by 100-300 mg every 1-7 days as tolerated (adjust dose in renal insufficiency). 1

Other options with limited evidence include:

  • Carbamazepine (may affect alprazolam metabolism) 1
  • Pregabalin 1
  • SSRIs (particularly paroxetine) for underlying anxiety 1
  • Trazodone 25-200 mg for short-term insomnia management 1

When to Pause the Taper

Clinically significant withdrawal symptoms signal the need to slow the taper rate or pause entirely. 1 Specific pause criteria include:

  • Moderate to severe withdrawal symptoms (anxiety, tremor, insomnia, etc.) 1
  • Severe psychological distress, depression, panic attacks, or suicidal ideation 1
  • Functional decline where patient cannot maintain daily activities 1

When pausing, maintain the current dose for 2-4 weeks until symptoms resolve, then restart at the same dose where the pause occurred—never increase the dose. 1

When to Refer to a Specialist

Immediate specialist referral is indicated for: 1

  • History of withdrawal seizures
  • Unstable psychiatric comorbidities
  • Co-occurring substance use disorders
  • Previous unsuccessful office-based tapering attempts

Critical Pitfalls to Avoid

  1. Never taper too quickly: Even a 10% reduction every 3 days resulted in only 24% of patients completing withdrawal successfully. 1

  2. Never use straight-line percentage reductions from the starting dose: This subjects patients to disproportionately large final decrements. 1

  3. Never abandon the patient: Even if tapering is unsuccessful, maintain the therapeutic relationship and consider maintenance therapy as a legitimate outcome. 1

  4. Never substitute another benzodiazepine at this low dose: The patient is already on a minimal dose, and substitution adds unnecessary complexity. 1

Realistic Timeline and Expectations

The taper will likely take 6-8 weeks minimum for this dose, possibly longer if withdrawal symptoms emerge. 1 Patient agreement and interest in tapering is a key component of success. 1 The goal is durability of the taper, not speed—tapers may be considered successful as long as the patient is making progress. 1

After successful discontinuation, patients typically experience improved psychomotor and cognitive functioning, particularly in memory and daytime alertness. 1

References

Guideline

Benzodiazepine Discontinuation

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Managing Benzodiazepine Withdrawal

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.